Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...
Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...
Jacob Berlin, PhD, CEO of Terray Therapeutics, explains that the critical element to “get right” for a preclinical drug discovery campaign is identifying molecules that rank best among the candidate ...
The pharmaceutical industry is a pillar of global health, valued at over $1.5 trillion. Within this sector, Analytical Research and Development (AR&D) ensures drug quality, safety, and efficacy. AR&D ...
In a major step forward for cancer drug discovery, researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug ...
New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...
It also exhibited robust selectivity, sparing FGFR1/4, and showed minimal off-target effects against a broad panel of kinases. In preclinical models, compound 10 displayed favorable pharmacokinetics, ...
The calcium-regulated protein drug (green) and tumor cell receptors (red) have bonded and internalization is underway, 40 seconds after administration. Cancer-fighting antibody drugs are designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results